Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

40 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
Warn P, Thommes P, Sattar A, Corbett D, Flattery A, Zhang Z, Black T, Hernandez LD, Therien AG. Warn P, et al. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6471-6482. doi: 10.1128/AAC.00974-16. Print 2016 Nov. Antimicrob Agents Chemother. 2016. PMID: 27527088 Free PMC article.
Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741.
Corbett D, Wise A, Langley T, Skinner K, Trimby E, Birchall S, Dorali A, Sandiford S, Williams J, Warn P, Vaara M, Lister T. Corbett D, et al. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00200-17. doi: 10.1128/AAC.00200-17. Print 2017 Aug. Antimicrob Agents Chemother. 2017. PMID: 28533232 Free PMC article.
SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
Sattar A, Thommes P, Payne L, Warn P, Vickers RJ. Sattar A, et al. J Antimicrob Chemother. 2015;70(6):1757-62. doi: 10.1093/jac/dkv005. Epub 2015 Feb 3. J Antimicrob Chemother. 2015. PMID: 25652749 Free PMC article.
Discovery of a Novel Metallo-β-Lactamase Inhibitor That Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae.
Everett M, Sprynski N, Coelho A, Castandet J, Bayet M, Bougnon J, Lozano C, Davies DT, Leiris S, Zalacain M, Morrissey I, Magnet S, Holden K, Warn P, De Luca F, Docquier JD, Lemonnier M. Everett M, et al. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e00074-18. doi: 10.1128/AAC.00074-18. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29530861 Free PMC article.
Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei.
Lackner M, Birch M, Naschberger V, Grässle D, Beckmann N, Warn P, Gould J, Law D, Lass-Flörl C, Binder U. Lackner M, et al. J Antimicrob Chemother. 2018 Nov 1;73(11):3068-3073. doi: 10.1093/jac/dky329. J Antimicrob Chemother. 2018. PMID: 30351438
Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B.
Denning DW, Warn P. Denning DW, et al. Antimicrob Agents Chemother. 1999 Nov;43(11):2592-9. doi: 10.1128/AAC.43.11.2592. Antimicrob Agents Chemother. 1999. PMID: 10543734 Free PMC article.
Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection.
Johnson EM, Oakley KL, Radford SA, Moore CB, Warn P, Warnock DW, Denning DW. Johnson EM, et al. J Antimicrob Chemother. 2000 Jan;45(1):85-93. doi: 10.1093/jac/45.1.85. J Antimicrob Chemother. 2000. PMID: 10629017
In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.
Corbett D, Wise A, Birchall S, Warn P, Baines SD, Crowther G, Freeman J, Chilton CH, Vernon J, Wilcox MH, Vickers RJ. Corbett D, et al. J Antimicrob Chemother. 2015;70(6):1751-6. doi: 10.1093/jac/dkv006. Epub 2015 Feb 3. J Antimicrob Chemother. 2015. PMID: 25652750 Free PMC article.
40 results
Jump to page
Feedback